Treatment of forehead/glabellar rhytide complex with combination botulinum toxin a and hyaluronic acid versus botulinum toxin a injection alone: a split-face, rater-blinded, randomized control trial

2013 ◽  
Vol 12 (4) ◽  
pp. 261-266 ◽  
Author(s):  
Meghan Dubina ◽  
Rebecca Tung ◽  
Diana Bolotin ◽  
Anne M Mahoney ◽  
Bailey Tayebi ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Botulinum Toxin ◽  
Randomized Control Trial ◽  
Botulinum Toxin A ◽  
Toxin A ◽  
Acid Versus ◽  
Randomized Control ◽  
Split Face

scholarly journals Comparison of intravesical instillation of hyaluronic acid with intradetrusor botulinum toxin A injection or cystoscopic hydrodistention for ketamine-associated cystitis

2020 ◽  
Vol 48 (11) ◽  
pp. 030006052097310
Author(s):  
Bingkun Li ◽  
Qu Leng ◽  
Chuanyin Li ◽  
Xiao Tan ◽  
Wei Su ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Intravesical Instillation ◽  
Lower Amount ◽  
Toxin A ◽  
Symptom Index ◽  
Detrusor Contraction ◽  
Contraction Group ◽  
Maximal Capacity

Objective This study aimed to compare the therapeutic effect of intravesical instillation hyaluronic acid with intradetrusor botulinum toxin A (BTX-A) injection or cystoscopic hydrodistention for ketamine-associated cystitis. Methods Thirty-six patients were evenly randomly divided into the BTX-A group or the hydrodistention group. Patients received 200 U BTX-A detrusor injections in the BTX-A group and cystoscopic hydrodistention in the hydrodistention group. Intravesical instillation of hyaluronic acid was administrated in both groups for eight times. Patients with involuntary detrusor contraction were divided into the persistent involuntary detrusor contraction group and resolved involuntary detrusor contraction group after treatment in 6 months. The predictors of persistent involuntary detrusor contraction were analyzed. Results Twelve months after treatment, the daytime frequency, Interstitial Cystitis Symptom Index, maximal capacity, and maximal cystometric capacity in the BTX-A group were significantly better than those in the hydrodistention group. Patients with resolution of involuntary detrusor contraction had a significantly shorter duration of ketamine, lower amount of fibrosis in pathology, and higher maximal capacity than those with persistent involuntary detrusor contraction 6 months after therapy. Conclusion Intravesical instillation of hyaluronic acid with intradetrusor BTX-A injection appears to be a preferable option for long-term effectiveness compared with cystoscopic hydrodistention.

Hyaluronic Acid Compound Filling plus Mesotherapy Versus Botulinum Toxin A for the Treatment of Horizontal Neck Lines: A Multicenter, Randomized, Evaluator-Blinded, Prospective Study in Chinese Subjects

2021 ◽  
Author(s):  
Yiming Li ◽  
Meirong Liao ◽  
Yijin Zhu ◽  
Jie Gao ◽  
Yang Song ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Botulinum Toxin ◽  
Treatment Group ◽  
Prospective Study ◽  
Botulinum Toxin A ◽  
Combined Treatment ◽  
Toxin A ◽  
Energy Devices ◽  
Patients Satisfaction ◽  
Age Related

Abstract Background Although energy devices and botulinum toxin-A (BTX-A) could alleviate the age-related laxity, ptosis, and platysmal bands, they have limited efficacy on horizontal neck lines. Objectives The purpose of this study was to investigate the efficacy, safety, and subject satisfaction of non-cross-linked hyaluronic acid (HA) compound filling plus mesotherapy combined treatment for the correction of horizontal neck lines, in comparison with BTX-A. Methods This multi-center, randomized, evaluator-blinded, prospective study enrolled female patients with moderate-to-severe horizontal neck lines corrected with either 2-3 sessions of non-cross-linked HA compound filling plus mesotherapy combined treatment or one session of BTX-A injection. Improvement of the neck lines grades, global aesthetic improvement scale (GAIS), patient satisfaction, and adverse events (AEs) were evaluated and compared on 1, 3, 6, and 10 months after the final treatment. Results Twenty-five patients received HA filling plus mesotherapy combined treatment and 23 received BTX-A injection. Compared with BTX-A, the HA compound filling plus mesotherapy combined treatment significantly improved the horizontal neck lines grades on all follow-up visits (P=0.000). Cases of different baseline grades (2, 2.5, and 3) demonstrated similar outcomes. The GAIS and patients’ satisfaction ratings were significantly higher for the HA combined treatment group (P=0.000). Significantly higher pain ratings, higher incidence, and longer recovery of AEs (erythema, edema, and ecchymosis) were noticed in the combined treatment group (P<0.001). No serious AEs occurred. Conclusions Compared with BTX-A, the HA compound filling plus mesotherapy combined treatment significantly improved moderate-to-severe horizontal neck lines and achieved a high level of patients’ satisfaction.

Botulinum Toxin-A and Scar Reduction: A Review

2018 ◽  
Vol 35 (4) ◽  
pp. 165-176
Author(s):  
Adam Honeybrook ◽  
Walter Lee ◽  
Julie Woodward ◽  
Charles Woodard
Keyword(s):  
Botulinum Toxin ◽  
Clinical Studies ◽  
Botulinum Toxin A ◽  
Case Series ◽  
Management Approach ◽  
Randomized Control Trials ◽  
Measurement Scales ◽  
Toxin A ◽  
Randomized Control ◽  
Scar Reduction

Pathologic scars remain a therapeutic enigma. Several therapeutic modalities have been described for the prevention and treatment of hypertrophic and keloid scars, but the optimal management approach has not yet been defined. This article reviews the newly emerging, off-label treatment, botulinum toxin-A (BTXA) for scar reduction. Eight in vitro, 9 in vivo animal, and 23 human clinical studies were deemed relevant to this review. Studies were conducted between 2000 and 2018. Clinical studies were of various methodologic qualities and comprised of 8 blinded randomized control trials, 7 cohort studies, and 7 case series/reports. Across all 23 human clinical studies, 521 patients were recruited, 20 studies were in favor of BTXA to reduce scars, 2 studies had equivocal results, and 1 study showed no benefit. The efficacy of BTXA to reduce scars appears promising and the clinical literature currently favors its use over placebo controls as a safe scar reduction alternative. The efficacy of this modality in comparison with other more widely accepted scar reduction methods is less clear. Further understanding of the molecular mechanism of action of BTXA upon scars and treatment modality cost-effectiveness comparisons remain to be explored. Large-scale randomized control trials of high methodologic quality, using objective measurement scales, must be produced to truly determine the efficacy of this innovative treatment.

Sign in / Sign up

Export Citation Format

Share Document